An efficient synthesis of gougerotin and related analogues using solid- and solution-phase methodology.
The first solid-phase synthesis of the natural product gougerotin has been accomplished. The synthetic route is versatile and allows for diversification at position C-4 of the heterocycle, C-6' of the sugar ring, and both residues of the peptidic moiety at N-4' in a parallel fashion. [structure: see text]
Migawa
Michael T
MT
Ibis Therapeutics, a Division of Isis Pharmaceuticals, Inc., 1896 Rutherford Avenue, Carlsbad, CA 52008, USA. mmigawa@isisph.com
Risen
Lisa M
LM
Griffey
Richard H
RH
Swayze
Eric E
EE
D000900:Anti-Bacterial Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D000935:Antifungal Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D001688:Biological Products / Q000138:chemical synthesis* / Q000494:pharmacology; D002176:Candida albicans / Q000187:drug effects; D020650:Combinatorial Chemistry Techniques; D004926:Escherichia coli / Q000187:drug effects; D011741:Pyrimidine Nucleosides / Q000138:chemical synthesis / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D001688:Biological Products; D011741:Pyrimidine Nucleosides; C004942:gougerotin